707 results on '"Esteva, Francisco J."'
Search Results
2. Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies
3. Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
4. Next-Generation HER2-Targeted ADCs for Treatment of Breast Cancer: Precision Oncology’s New Frontier
5. Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
6. Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
7. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
8. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
9. Are Biosimilars the Future of Oncology and Haematology?
10. Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study
11. Immunotherapy and targeted therapy combinations in metastatic breast cancer
12. Breast cancer risk in relation to plasma metabolites among Hispanic and African American women
13. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study
14. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis
15. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β
16. TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
17. A new paradigm for classifying and treating HER2‐positive breast cancer
18. Supplemental Methods and Figure Legends from Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition
19. Data from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
20. Supplemental Figures S1-S8 from Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition
21. Supplementary Figure 1 from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
22. Supplementary Figure Legend from Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
23. Data from Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition
24. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial
25. A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab
26. Supplementary Tables 1-17, Figures 1-14, Methods from Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer
27. Supplementary Table 4 from Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
28. Supplementary Table 1 from Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
29. Supplementary Figure 1 from Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer
30. Supplementary Data from Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors
31. Supplementary Table 3 from Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
32. Supplementary Table from Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer
33. Supplementary Data from Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer
34. Data from Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
35. Supplementary Figure 1 from Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
36. Supplementary Figure 2 from Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
37. Supplementary Materials, Figure Legends 1-3 from Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
38. Clinical utility of gene-expression signatures in early stage breast cancer
39. Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy
40. Detection and Clinical Implications of Occult Systemic Micrometastatic Breast Cancer
41. Contributors
42. Ribociclib Plus Fulvestrant for HR+, HER2- Advanced Breast Cancer
43. Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
44. Impact and Challenges in Assessing Tumor Purity by Next-Generation Sequencing
45. Herceptin
46. Serum Tumor Markers and Circulating Tumor Cells
47. Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
48. Serum and Tissue Markers for Breast Cancer
49. Herceptin
50. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.